BioOutsource Ltd., a provider of contract testing services for the biopharmaceutical industry, has been acquired by Sartorius Stedim Biotech, an international supplier for the biopharmaceutical industries. BioOutsource provides contract testing services to global biopharmaceutical clients in order to monitor the safety and quality of biologic drugs and vaccines. This acquisition will develop Sartorius’ service offering throughout the drug development pathway.

“We are delighted to have found a strong partner with a broad customer base, international reach and a powerful brand,” said Gerry MacKay, chief executive officer of BioOutsource. “With Sartorius Stedim Biotech we will be able to scale our business to the next level and invest in new adjacent services. As a part of this group, we will have the opportunity to work with more international customers particularly in areas like the U.S. and Asia where there is significant investment in biosimilar development and manufacturing.”

Reinhard Vogt, member of Sartorius’ board, said, “By adding contract testing services, we will be able to support our biopharma clients even better in their drive to fast-track their new drug candidates through the development and clinical test phases and facilitate lot release testing in large scale manufacturing. The highly qualified team at BioOutsource will ideally complement our expertise, and we are looking forward to working with them.”